On May 12, 2017, Avadel Pharmaceuticals plc, a public limited
company organized under the laws of Ireland (the “Company”),
filed with the Irish Companies Registration Office, to certain
requirements of the Irish Companies Act 2014, the Initial
Financial Statements (as hereinafter defined) of the Company,
consisting of certain unconsolidated financial information of the
Company for the period from December 1, 2015 (the Company’s date
of incorporation) to December 31, 2016. The Initial Financial
Statements of the Company comprise the statement of directors’
responsibilities, the statement of comprehensive income, the
statement of changes in equity, the statement of financial
position, the statement of cashflows and notes to the financial
statements (collectively, the “Initial Financial Statements”),
which are attached hereto as Exhibit 99.1 and incorporated by
reference herein. Unlike the Company’s consolidated financial
statements included in the Company’s filings under the
Securities Exchange Act of 1934, as amended (the “Exchange
Act”), which present financial information on a consolidated
basis with the Company’s subsidiaries and are prepared in
accordance with generally accepted accounting principles in the
United States, the Initial Financial Statements provide certain
unconsolidated Company-only financial information and have been
prepared in accordance with accounting standards issued by the
Financial Reporting Council and promulgated by Chartered
Accountants Ireland (Generally Accepted Accounting Practice in
Ireland). Therefore, the information in this Item 7.01, including
Exhibit 99.1, may not be comparable to, but should be read in
conjunction with, the information contained in the Company’s
filings under the Exchange Act.

The information in this Item 7.01, including Exhibit 99.1, is
being furnished and shall not be deemed to be “filed” for
purposes of Section 18 of the Exchange Act, or otherwise subject
to the liability of that Section, nor shall such information be
deemed to be incorporated by reference into any registration
statement or other document filed under the Securities Act of
1933, as amended, or the Exchange Act, except as otherwise stated
in that filing. The Company does not undertake any obligation to
update the information contained in this Item 7.01, including
Exhibit 99.1.

99.1

Avadel Pharmaceuticals plc Initial Financial Statements for the period from December 1, 2015 to December 31, 2016.